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The presence of hepatic soluble cytochrome P450 was investigated in the rats that were pretreated with 
CCL, CS2 and DENA + PCBs. The dithionite-reduced CO difference spectrum of the hepatic 204000 x 
g supernatant of these rats showed its maximum at 455 nm. Aniline and hexobarbital could react with the 
hepatic 204000 x g supernatant o give the substrate binding spectra of P450; differences were observed 
between the substrate-induced ifference spectra of the 204000 x g supernatant and that of the microsomal 
fraction. These results indicate the existence of a hepatic soluble P450. 
Cytochrome P450, soluble (Rat liver) Difference spectrum 
1. INTRODUCTION 
Cytochrome P450 (P450), the major hemopro- 
tein present in mammalian endoplasmic reticulum 
functions as a terminal component of the 
microsomal mixed-function oxidase system [I]. 
Soluble P450 is known to be present in 
microorganisms [2-71, but a soluble form of mam- 
malian P450 has not been reported. 
A soluble protein, extracted from liver 
cytoplasm of male rats which were intoxicated with 
CCL, stimulated microsomal NADPH oxidase (81. 
This stimulation was inhibited by carbon monox- 
ide, suggesting that the soluble protein extract con- 
tained a carbon monoxide-sensitive component, 
such as hemoprotein [8]. Here, I show that the 
204000 x g supernatant of the rat liver 
homogenate contains a soluble P450 which results 
from the impairment of microsomal P450. 
2. MATERIALS AND METHODS 
Male Wistar rats (300-350 g body wt) were 
divided into 5 groups. Each group was composed 
of 6 rats. Group 1 was the control while other 
groups were experimental. CCL+, CS2 (carbon 
disulfide) and DENA (diethylnitrosamine), known 
to impair microsomal P450 [9-l 11, were ad- 
ministered to group 2-5. Group 2 was given CC4, 
group 3 was given CS2, group 4 was given DENA, 
and group 5 was given DENA and PCBs. CC14 
(1 ml/kg body wt) was injected into the rats in- 
traperitoneally; 7 days after the CC4 injection, the 
rats were decapitated. Livers were immediately 
perfused in situ with ice-cold 0.9% NaCl. A 20% 
liver homogenate was made in ice-cold 0.15 M 
KCl, 10 mM Tris-HCl buffer (pH 7.5). This was 
centrifuged at 10000 x g for 20 min, and a soluble 
fraction was prepared from the 10000 x g superna- 
tant by centrifuging it further at 204000 x g for 
240 min to avoid contamination of free ribosomes. 
The resulting 204000 x g supernatant was saved 
for a soluble fraction and the sedimented 
microsomes were resuspended in 0.15 M KCl, 
10 mM Tris-HCl buffer (pH 7.5). Group 3 receiv- 
ed CS2 (200 mg/kg body wt) intraperitoneally; 10 
days after the CS2 injection, group 3 was sacrific- 
ed. DENA (Tokyo Kasei Chemical Co.) was of- 
fered to groups 4, 5 in the drinking water at 
50 ppm for 5 weeks. Group 5 received thereafter 
PCBs (Kanechlor 500, Kanegafuchi Chemical Co., 
Osaka) for 5 weeks; 0.2 ml 5% PCBs was ad- 
ministered in olive oil to group 5 by gastric intuba- 
tion twice a week. Ten weeks after the DENA ad- 
ministration, groups 4, 5 were then sacrificed; the 
204000 x g supernatant fraction and microsomal 
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fraction were then prepared. The normal 204000 x 
g supernatant and the normal microsomal fraction 
were prepared from normal rats. 
P450 was determined from the carbon 
monoxide-induced difference spectrum of 
dithionite-reduced 204000 x g supernatant or 
microsomes assuming a molar extinction coeffi- 
cient of 91 mM_’ .cm-’ between 450 and 490 nm 
WI. 
Difference spectra of hexobarbital and aniline 
with the 204000 x g supernatant and with the 
microsomes were measured as follows. The 204000 
x g supernatant (10.8 mg protein/ml) was divided 
equally into sample and reference cuvettes and 
scanned between 500 and 350 nm to produce a 
baseline using Shimazu UV-190 double beam spec- 
trophotometer. Hexobarbital and aniline were 
added at 5 mM to the sample cuvette, while the 
reference cuvette received solvent in appropriate 
amounts. Microsomes were suspended in 0.15 M 
KCl, 10 mM Tris-HCl buffer (pH 7.5) to 
1.5-2.2 mg protein/ml. Reaction temperature was 
22°C. 
3. RESULTS AND DISCUSSION 
3.1, Dithionite-reduced carbon monoxide 
difference spectrum of the hepatic 
204000 x g supernatant (figSI) 
The hepatic 204000 x g supernatant was ex- 
tracted at 7 days after the CC4 injection. The dif- 
ference in absorbance at 460 nm was low at 2 min 
after the addition of dithionite (4 mg), but 
gradually reached its maximum value after 14 min; 
its absorbance change represented a blue shift 
from 460-455 nm. The time which is needed for 
the change to develop maximally shortened when 
10 mg dithionite was added; in which case 4 min 
were needed to reach its m~imum. In [13], slow 
reduction of yeast P450 was observed on addition 
of Triton X-100. These results suggested that the 
time dependency of the carbon monoxide dif- 
ference spectrum was due to the slow reduction of 
the heme. The dithionite-reduced CO difference 
spectrum of the 204000 x g supernatant of the 
groups 3, 4 and 5 also showed its maximum at 
455 nm. However, the dithionite-reduced CO dif- 
ference spectrum of the normal 204000 x g super- 
natant did not show its absorbance maximum at 
450-500 nm; that is, control group 1 did not 
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Fig. 1. Time dependency of carbon monoxide-induced 
difference spectrum of dithionite-reduced hepatic 
soluble fraction extracted from CC&treated rats. A 
3 ml sample of solubIe fraction was placed in each of 
two spectrophotometer cuvettes and the baseline 
between 400 and 500 nm was recorded using Shimazu 
UV-190 double-beam spectrophotometer. After that, 
carbon monoxide was bubbled (at 1 bubble/s) through 
the sample cuvette for 1 min and 4 mg sodium dithionite 
was added to both cuvettes. The scanning was repeated. 
Soluble fraction from CCL+-treated rats had 10.8 mg 
protein/ml; a control spectrum (-- -) obtained from 
normal rats and measured after 14 min contained 
11.4 mg protein/ml. Spectrophotometry was carried out 
at 22°C. 
possess the heme compound evident in the 204000 
x g supernatant. Thus it is suggested that the 
hepatic 204000 x g supernatant of treated rats 
might contain a P450-like hemoprotein. 
3.2. Aniline and hexobarbital-induced ifference 
spectra of the hepatic 204000 x g supernatant 
Aniline and hexobarbital substrates were then 
tested for reaction with the hepatic 204000 x g 
supernatant to give the characteristic substrate- 
binding spectra of P450. According to [ 14- 171, the 
spectral changes induced by substrate are due to 
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the interaction between the P450 molecule and the 
substrate. In fig.2, the hepatic 204000 x g superna- 
tant was extracted from rats at 7 days after the 
CC4 injection. When 5 mM hexobarbital was add- 
ed to the sample cuvette, it induced an anomalous 
spectral change; absorption maxima and minima 
occurred at 410 nm and 430 nm. Such anom~ous 
spectral change induced by hexobarbital has been 
reported in [18]. P450 extracted once with 
I-butanol and twice with acetone from hepatic 
microsomes of 3-methylcholanthrene-treated rats 
exhibited an anomalous spectral change (410 nm 
peak, 430 nm trough) on addition of hexobarbital 
in the absence of 25% glycerol 1181. However, 
5 mM aniline induced a typical type II spectral 
change (390 nm trough, 420-425 run peak). Nor- 
mal hepatic 204000 x g supernatant from the 
group 1 rats, however, did not show the substrate- 
induced spectral change. 
In the event that the hepatic 204000 x g superna- 
tant was simply contaminated by microsomal 
fragments, the same substrate-induced ifference 
spectra would then be expected for that observed 
with the microsomal fraction. However, in certain 
cases some differences between the substrate- 
induced difference spectra of the 204000 x g 
supernatant and that of the microsomal fraction 
were evident (fig.3). The 204000 x g supernatant- 
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Fig.2. Difference spectra due to the presence of 5 mM 
hexobarbital (A) and 5 mM aniline (B) in a soluble 
fraction from CCL-treated rats. Soluble fraction had 
9.8 mg protein/ml. 
of the microsomal fraction (fig.3). In group 4, the 
aniline-binding spectrum was not observed in the 
204000 x g supernatant from l-10 mM; however, 
it was observed in microsomes, where the 
magnitude of the spectral change was dependent 
on the concentration of aniline. Further, the posi- 
tions of the peak and trough of the hexobarbit~- 
induced difference spectrum in the supernatant 
were not the same as that in the microsomes. In 
group 5, l-10 mM hexobarbital induced a type II- 
like spectral change in the supernat~t, but it in- 
duced a typical type I spectral change in micro- 
somes. This type I spectral change did not change 
over l-10 mM hexobarbital, while the magnitude 
of spectral change was dependent on the concen- 
tration of hexobarbital in this range. This 
hexobarbital-induced type II-like spectral change 
was reported in 1191. When rat liver microsomes 
were extracted with isooctane, the resultant 
preparation was essentially devoid of the ability to 
produce a type I difference spectrum upon addi- 
tion of hexobarbital 1191; a type II spectral change 
was obtained at high concentrations of hexobar- 
bital [19]. The effect of cytosol on the microsomal 
spectral change was almost negligible. These 
results suggested that P450 in the 204000 x g 
supernatant was not the result of contamination by 
microsomes. 
Since the hepatic 204000 x g supernatant con- 
tained comparatively low amounts of oxy- 
hemoglobin and P420, the substrate-binding spec- 
tra of oxyhemoglobin and P420 was investigated. 
In the case of oxyhemoglobin, hexobarbital and 
aniline induced a spectral change which included 
an absorption minimum at 405 nm, but no absorp- 
tion maximum. In the case of P420 which was 
made by treatment of mercuric chloride (1OOpM) 
with normal microsomes for 30 min at 37°C (70~0 
of P450 was converted to P420), anomalous spec- 
tral changes were observed; hexobarbital yielded a 
peak at 410 nm, while aniline yielded a trough at 
410 nm. Soluble P420 did not show the substrate- 
binding spectral changes in [ZO]. These results in- 
dicated that oxyhemoglobin and P420 which were 
present in the 204000 x g supernatant did not show 
the same substrate-induced spectral change as the 
supernatant showed. 
Purification of the soluble P450 in the 204000 
x g supernatant by n-octylamine affinity chroma- 
tography and the difference between the soluble 
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Fig.3. Differences between the substrate-induced ifference spectra of the soluble fraction and that of the microsomal 
fraction. The upper part of each figure represents the soluble fraction-substrate binding spectra. The lower part 
represents the microsomal substrate binding spectra for (A) rats treated with DENA, (B) rats treated with DENA and 
PCBs. Experimental conditions were as in fig. 1. Microsomes were suspended in 0.15 M KCl, 10 mM Tris-HCl buffer 
(pH 7.5) to 1.5-2.2 mg protein/ml. Reaction temperature was 22°C. 
Table 1 
The relationship between a soluble and a microsomal P450 (nmol/mg protein) 
Microsomal P450 P420 Supernatant 
Control 1.000 * 0.33 (n.d.) n.d. 
(462-464 nm)a 





0.301 f 0.13 0.663 f 0.43 nd. 
(462-464 nm)” 
0.685 + 0.10 0.164 f 0.02 0.0018 k 0.00001 
(452-454 nm)a 
1.08 * 0.01 (n.d.) 0.092 f 0.0060 
(455 nm)a 
a Peak of CO difference spectrum 
n.d., not detected 
All values are expressed as the average of 5 experiments + SD 
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The aniline hydroxylase activity of normal and Ccl, microsomes in the presence of hepatic 204000 x g supernatant 
extracted at 7 days after CC4 injection or extracted from normal rat 
Added (2.5 ml) 
Normal microsomes CC4 microsomes 
Aniline P4.50 Aniline P450 
hydroxylase hydroxylase 
0.15 M KCI, 10 mM buffer 
Tris-HCl (PH 7.5) 
Normal S 
7 Days S 
0.73 -t 0.15 0.943 0.12 f 0.059 0,204 
0.58 f 0.18 0.825 0.15 * 0.088 0.246 
1.08 f 0.03 1.040 0.67 * 0.088 0.810 
Experimental conditions were described inthe text, except that the reaction was for 12 min at 37”C, aniline was 1 mM, 
and the total volume was 4.5 ml. Microsomal protein was 1.5 mg/mI. Normal supernatant protein was 10.1 mg and 
7 days (after the CC4 injection) supernatant protein was 9.75 mg. All values were the mean of 5 expt ~fr SD. P450 value 
is expressed as the average of 3 expt. Aniline hydroxylase activity: nmol p-aminophenol formed. min-’ . mg protein-‘. 
Activity of aniline hydroxylase was measured as in [21] 
P450 and microsomal P450 are being studied; the 
presence of P450 in the 204000 x g supernatant 
has been confirmed (in preparation). The 
204000 x g supernatant shows neither glucose 
6-phosphatase activity nor the spectral changes 
associated with cytochrome bs, providing further 
support to the conclusion that microsomal 
fragments do not contaminate the supernatant. 
The above phenomena were not observed at the 
first stage of drug administration, but at the 
recovery stage of microsomal P450 (table 1). 
Would addition of this P450-like hemoprotein 
to the microsomes next result in an increase in the 
activity of the microsomal aniline hydroxylase? 
Normal and CCL-treated microsomes, which were 
extracted 1 day after the CC4 injection, were add- 
ed to the 204000 x g supernatant extracted at 7 
days after the CC4 injection. The mixture was in- 
cubated at 25°C for 10 min, then centrifuged at 
204000 x g for 90 min. The content of the 
sedimented microsomal P450 and the activity of 
aniline hydroxylase were measured (table 2). The 
normal and CC4 xnicrosomes added to the 7 day 
supernatant had the highest activity of aniline 
hydroxylase and showed the highest P450 content. 
These results indicated that the increase in aniline 
hydroxylase activity and P450 content was due to 
the incorporation of P450 present in the 204000 x 
g supernatant. 
Hepatic soluble P450 is present in the rats 
pretreated with CC4, CSz, DENA and DENA plus 
PCBs. This hepatic soluble P450 was not con- 
taminated by microsomal fragments. 
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